Purpose:The aim is to report the clinical characteristics, presenting signs, treatment efficacy, toxicities, the overall outcomes, and survival rate in a population based group of children with neuroblastoma who have received treatment at CCCL (Children Cancer Center of Lebanon) in AUBMC ( American University of Beirut). The outcomes include recurrence rate, treatment side effects, failure rate, and survival.

Methods: All children who were diagnosed with neuroblastoma and received treatment at CCCL from January 1, 2002 to December 31, 2014. Data will be extracted from the medical records.

Results:We will compare our results at CCCL- as a tertiary medical center in the middle east with a multidisciplinary care system - with those published in the literature in both developing and developed countries. We will indentify whether our outcome measures require any future treatment modification in our patient population and to determine possible barriers to adequate care in our setting.

Conclusion:We will evaluate how the treatment allocation, toxicities, and outcome in our setting compares to that described in prospective multicenter studies. This study may identify areas for future treatment modification in our patient population, as well as possible barriers to adequate care in our setting.

Children with Neuroblastoma who have been diagnosed and treated at Children Cancer Center of Lebanon (CCCL) at American University of Beirut (AUBMC), between January 2002- December 2014.

The study population includes children who were diagnosed with neuroblastoma and received treatment at CCCL, between January 2002- December 2014. We expect about 45 patients to be identified.

Data on demographics, histological features, stage of the tumor, primary site of involvement, tumor size (based on imaging), presenting clinical signs, MYCN gene status, treatment given, local control (surgery and/or chemotherapy and/or radiation), transplant regimen and toxicity, recurrence of the tumor, and overall outcome. All data will be extracted retrospectively from the medical records.

The response of our target population to the treatment and over all outcomes will be determined and statistically analyzed then we will compare our results to that published in the literature. Assessment of OS and EFS will be done by Kaplan meier analysis, evaluation of features associated with outcome will be done by-test or Chi-square analysis, as applicable.